June 06, 2016 – – Thomas Moverman of LipsigLawyers.com recently commented on the need for greater safety precautions on construction work sites due to the sharp increase in fatal injuries that have occurred in the last 5 years.

As reported by NBCDFW.com, on May 11th of 2016, a local Dallas construction worker was on site near a forklift in Rowlett at about 8:15 AM. The local worker has been presumed dead after a forklift fell over and crushed the 36-year- old man. Authorities have not identified the victim, but they have indicated that the accident took place at the building site of a proposed project for a number of apartment buildings called Terra Lago. The site is located on the west bank of Lake Ray Hubbard close to the intersection of Texas 66 and Scenic Drive.

Fatalities in the construction industry have increased recently. OSHA (Occupational Safety & Health Administration) reports that there were 874 deaths in construction in 2014 which accounts for over 20% of worker fatalities in all private industries. Out of those 874 deaths, over 58% of them occurred from the “Fatal Four.” Eliminating the ‘Fatal Four’ (falls, electrocutions, being struck by objects, and being caught between equipment), would result in nearly 365 fewer construction-related deaths per year, according to the Bureau of Labor Statistics.

Lipsig, Shapey, Manus, & Moverman are committed to offering assistance to individuals and their families who have been affected by construction accidents. Attorney Thomas Moverman notes that although OSHA regulations have decreased the average number of worker deaths per day from 38 to 13 since 1970, there are still significant improvements that can be made to bring that number much closer to 0. The firm has great success representing victims of construction accidents, for instance, they recently won a verdict that awarded a victim 2.6 million dollars in compensation after the victim fractured his ribs and injured his spine due to a scaffolding fall due to a defect. Lipsig, Shapey, Manus, & Moverman are offering free legal consultations to all individuals who have been affected by construction accidents.

For more information on construction injuries, or for a consultation, contact an attorney with Lipsig Shapey, Manus & Moverman at (646)-846-4496.

###

Contact LipsigLawyers.com:

Marc Freund
877-711-9545
mfreund@lipsig.com
40 Fulton St, New York, NY 10038

ReleaseID: 60010456

June 06, 2016 – – TheProductLawyers.com reports on a lawsuit filed in the state of Vermont by the daughter of a deceased Xarelto user, her father. She claims he died from an uncontrollable brain bleed which was caused by his use of the drug when he sustained an injury.

In her lawsuit paperwork, the plaintiff claims her father was prescribed Xarelto to treat his atrial fibrillation, a heart condition that can sometimes put patients at risk for blood clots or stroke. Blood thinners, such as Xarelto, are used as a preventative option to prevent clotting or stroke. Her lawsuit has been filed against the makers of the drug, Bayer AG and Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation.

She further states in her court filing, that her father had only been using Xarelto for a brief period. After his fall and the brain bleeding occurred, he was diagnosed with an intracerebral hemorrhage. He eventually died from the bleeding.

Many blood thinners, such as warfarin, are accompanied with an antidote via the use of Vitamin K, which acts as to counter the effects of the blood thinner and allows blood to form clots. At the time of the plaintiff’s father’s death, there was no antidote released with Xarelto, leaving doctors with no option other than blood transfusions or surgery.

The plaintiff is claiming that the drug’s manufacturers were negligent in releasing a drug on the market with no known antidote, which can create potentially lethal bleeding dangers, as was the case with her father.

In addition to the plaintiff’s lawsuit, many others have been filed claiming the drug caused uncontrollable bleeding. 550 lawsuits have been consolidated into a mass tort program in Philadelphia, PA, along with 2,800 others that have been grouped together in a Multidistrict Litigation (MDL 2592).

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010450

June 6, 2016 – A new study suggests that proton pump inhibitors may accelerate aging of the cells that line the blood vessels, an occurrence which could explain findings linking drugs like Nexium to kidney failure, heart attack, and other dangerous complications. According to a report published last month in Circulation Research, the authors of the study cultured endothelial cells, which line the walls of the blood vessels and produce a substance that prevents plaques or blood clots from adhering. The cultured cells were then exposed to typical doses of Nexium for an extended period of time.

The experiment indicated that long-term exposure to proton pump inhibitors impaired the ability of lysosomes to produce the acid which would normally clear waste products from the cells. The resulting build-up of waste caused the endothelial cells to age rapidly, which could interfere with their ability to protect blood vessels. The study authors did not observe a similar phenomenon in cultured cells that were exposed to another class of heart burn drugs called H2 blockers, which includes medications like Zantac and Pepcid.

“This study is just the most recent to suggest that long-term use of Nexium and other proton pump inhibitors could be associated with serious health consequences. It is clear that more research is needed in this area,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently investigating potential legal claims on behalf of individuals who may have suffered serious kidney failure or other renal complications due to their use of Nexium or another proton pump inhibitor.

Proton Pump Inhibitors and Kidney Complications
Proton pump inhibitors are intended for the short-term treatment of GERD and other disorders related to the over-production of stomach acid. In addition to Nexium, drugs in this class include:

Over-the-counter formulations, including Nexium 24HR, Prilosec OTC, and Prevacid 24HR, are also available.

According to the U.S. Food & Drug Administration (FDA), 1 in 14 Americans have used a proton pump inhibitor. However, evidence suggests that as much as 70% of this use may be inappropriate, with many patients taking the drugs for long periods of time. A growing body of research has raised concerns that the inappropriate use of Nexium and similar medications could pose serious health consequences. In April, for example, a study published in the Journal of the American Society of Nephrology linked extended use of proton pump inhibitors with a 96% increased risk of renal failure and a 28% increase in the risk for chronic kidney disease when compared to H2-blockers. In January, research that appeared in JAMA Internal Medicine also found that the medications might increase the risk of chronic kidney disease by as much as 50%.

Bernstein Liebhard LLP is now offering free legal reviews to individuals who developed renal failure or other kidney complications that may be related to their use of Nexium or another proton pump inhibitor. To learn more about filing a Nexium lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal’s “Plaintiffs’ Hot List,” recognizing the top plaintiffs firms in the country. This year’s nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
www.rxinjuryhelp.com
https://plus.google.com/115936073311125306742?rel=author

GET IN TOUCH
Sandy Liebhard
RX Injury Help
800-511-5092
http://www.rxinjuryhelp.com/

Release ID: 246724

June 06, 2016 – – TheProductLawyers.com reports on serious safety concerns and numerous lawsuits that have been filed related to the use of Xarelto, a blood-thinning drug manufactured by Bayer AG and Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation. To date, more than 2,800 cases have been filed in federal courts across the nation claiming that the drug caused dangerous and often times fatal uncontrollable bleeding. Since there have been so many lawsuits filed against the manufacturers for the same reason, these cases have been consolidated in a multidistrict litigation (MDL). In addition to MDL 2592, a mass tort litigation program has been formed in Philadelphia, PA combining more than 550 more Xarelto lawsuits together.

Xarelto is generally prescribed to treat atrial fibrillation, that can, at times, cause blood clots or stroke. Blood thinners are prescribed as a preventative measure in these types of medical situations.

In one Xarelto case, the plaintiff has filed a lawsuit on behalf of her father, who she claims in her court documents died as a result of excessive bleeding from an injury he experienced that caused bleeding in his brain. Doctors could not get his blood to clot due to his use of Xarelto.

Other blood thinners, such as warfarin, were released on the market with an anecdote such as Vitamin K, that would counteract this class of blood thinner and thus allow the patient to form blood clots to stop the bleeding. Xarelto, on the other hand, did not have any such antidote at the time of its release on the market. The only recourse was for doctors to resort to life-threatening surgical procedures or transfusions of blood.

The plaintiff in the Vermont case states that the drug’s manufacturers were negligent in knowingly releasing a drug with no known antidote that could cause uncontrollable and fatal bleeding.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010449

June 06, 2016 – – TheProductLawyers.com reports on the immense number of cases being filed against Bayer AG and Johnson and Johnson Corporation subsidiary Janssen Pharmaceuticals related to Xarelto. The anticoagulant has been alleged to have caused instances of uncontrolled and very dangerous bleeding in patients using it. Resulting from the large number of cases, a group of plaintiffs that had filed individual lawsuits petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) in October 2015 to consider consolidating the cases since all of the 2,800 or more of the suits filed involved the same defendants and very similar allegations about the drug.

The petitioners asked that all the cases involved be under the jurisdiction of a court in the Southern District of Illinois. However, the defendants in the case argued against this move since they were located in New Jersey and felt it would be more prudent to have them assigned to a New Jersey court.

In a decision handed down on December 12, 2015, the judicial panel agreed with the petitioners and opted to consolidate and centralize all the bleeding cases involving Xarelto to the Honorable U.S. District Court Judge Eldon E. Fallon in the Eastern District of Louisiana. The panel expressed its confidence in Judge Fallon to prudently and effectively oversee the consolidation of MDL 2592.

The JPML felt that having each case heard individually would only serve to increase the amount of time spent by those parties involved in the cases as well as the legal expenses that would be incurred. The panel also felt such a consolidation would reduce the lengthy and sometimes very expensive discovery processes.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010448

June 06, 2016 – – All white household size and marine toilets from Raritan Engineering, a business based in Millville, NJ, now come with a Slow Close Seat and Lid feature. This is to prevent slamming of toilet seats, which is usually startling particularly on board a boat. At night, the slamming noise can disturb the sleep of the crew. When released, Raritan’s Slow Close Seat and Lid gently lowers to the bowl and the final contact is whisper-quiet. It is the finishing touch to the well-appointed marine head.

Kim Shinn from Raritan Engineering says: “We have designed a truly silent toilet seat and are proud to say that slamming toilet seats are now a thing of the past. Our Slow Close Seat and Lid technology means that seats can no longer slam, either after someone uses the toilet or when the seas are heavy and the boat sways. We’re happy to see how popular the seat is already becoming.”

Designed specifically for marine use, a special stopper locks the comfortable, ergonomic seat in place when someone is sitting on it. This counters the sideways motion often encountered on a boat and protects the hinges from undue strain. The Slow Close Seat and Lid is manufactured from durable HDF (high density fiberboard), quality finished in gleaming white and built with stainless steel fasteners to prevent corrosion.

While the new white Raritan marine and household size toilets now come standard with a Slow Close Seat and Lid, the seats are also available separately to upgrade an older unit. The household size seat & cover will fit the company’s manual and electric toilets with standard style bowls, and even other brands with similarly sized seats. A bone version is planned.

For 58 years, Raritan Engineering has manufactured a wide range of innovative boating equipment. A pioneer in marine sanitation, it has been awarded numerous patents on its ground-breaking products. The marine size seat & cover is just the latest in their long list of products. Boats and ships around the world are now equipped with Raritan products, and many people within the marine world always look out for the latest developments from the company.

###

Contact Raritan Engineering:

Kim Shinn
856-825-4900 ext.202
kim@raritaneng.com
Main Office & Plant:
530 Orange St.
Millville, NJ 08332

ReleaseID: 60010311